<DOC>
	<DOCNO>NCT00684528</DOCNO>
	<brief_summary>Comparison effectiveness one anti-diabetic drug ( Metformin , To combination drug additional drug ( Janufer ) , In community setting .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Active-Comparator ( Metformin ) Controlled , Clinical Trial Study Efficacy Safety Strategy Start Patients With Type 2 Diabetes Mellitus Janumet™ Compared Metformin</brief_title>
	<detailed_description>This randomize , double-blind , active-comparator ( metformin ) control study drug-naïve patient T2DM HbA1c ≥ 7.5 % . The duration study 55 week , include 1-week screening period ( Visit 1 Visit 2 ) 54 week double-blind , active treatment period . At Visit 2/Day 1 patient meet enrollment criterion randomize 1:1 ratio one two active treatment group : 1 . JANUMET™ ( fixed-dose combination sitagliptin/metformin ) 2. metformin . The start fixed-dose combination sitagliptin/metformin 50/500 mg administer twice-daily up-titrated dose 50/1000 mg b.i.d . 4 week . The start dose metformin 500 mg twice-daily up-titrated dose 1000 mg b.i.d . 4 week . Patients tolerate JANUMET™ dose least 50/500 mg b.i.d . metformin dose least 500 mg b.i.d . 6 week randomization throughout study discontinue . During double-blind treatment period patient remain study medication , investigator allow add antihyperglycemic agent improve glycemic control necessary . The investigator schedule additional visit initiate additional antihyperglycemic agent monitor glycemic control time study period . There fixed visit schedule , 7 clinical visit recommend . It also recommend perform first visit active treatment 6 week randomization visit schedule visit every 3 month . All clinical lab data obtain use `` Clalit health care information system '' .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>All laboratory measurement perform overnight fast ≥ 10 hour duration . Patients laboratory screening values/findings meet protocol inclusion criterion may , discretion investigator , one repeat determination perform . If repeat value satisfies criterion may continue screen process . Only laboratory test meeting inclusion repeat ( entire panel ) . Glucose Metabolism Therapy Criteria Patient history type 1 diabetes mellitus history ketoacidosis . Patients Requiring Specific Treatments Patient symptomatic hyperglycemia require immediate initiation insulin therapy . Patient history intolerance hypersensitivity metformin sitagliptin contraindication use metformin . Concomitant Disease Organs Systems Patient medical history active liver disease ( exclude hepatic steatosis ) . Patient severe active peripheral vascular disease ( e.g. , manifested claudication minimal activity , nonhealing ischemic ulcer , disease likely require intervention bypass angioplasty ) . Patient unstable acute congestive heart failure . Patient history malignancy without documentation remission/cure . Other Criteria Patient pregnant , positive urine pregnancy test Visit 1 , expect conceive within project duration study , breast feeding . Exclusion Criteria Based Lab Abnormalities Patient increase serumcreatinine and/or decrease estimate creatinine clearance . If screening lab repeat , last laboratory draw/result use inclusion.§ Either elevate Creatinine decrease estimate creatinine clearance lead exclusion patient . Patients whose serum creatinine meet exclusion criterion , whose estimate creatinine clearance &lt; 60 mL/min ≥50 mL/min , may measure creatinine clearance ( i.e. , base upon 24hour urine collection ) . These patient may eligible measured creatinine clearance ≥60 mL/min . At Visit 2 Patient site fingerstick glucose &lt; 130 mg/dL ( 7.2 mmol/L ) &gt; 320 mg/dL ( 17.8 mmol/L ) . Note : If patient meet exclusion criterion AND investigator believe value reflect patient 's recent glycemic control base upon recent SBGM value and/or Visit 1 FPG value , patient exclude time . The current visit change `` Unscheduled visit '' patient reschedule Visit 2 . If , reschedule Visit 2 , patient meet exclusion criterion , patient MUST exclude . Patient positive urine pregnancy test . Patient develop new medical condition , suffer change status establish medical condition , develop laboratory abnormality , require new treatment medication Visit 1 Visit 2 meet previously describe study exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>DM 2</keyword>
	<keyword>Metformin</keyword>
	<keyword>Januvia</keyword>
	<keyword>Community set</keyword>
	<keyword>newly diagnose diadetics , diabetes patient treat last year</keyword>
</DOC>